Mikanisal (Ketoconazole)

Ketoconazole, the active ingredient in Mikanisal, is an imidazole antifungal presented as a topical formulation for skin use. It treats fungal skin infections such as dermatophyte infections (including tinea corporis and tinea cruris), seborrheic dermatitis, and pityriasis versicolor in both adults and children.

GNH USA supplies Mikanisal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product is manufactured under EU quality standards and distributed to global markets, ensuring consistent potency and safety.

Mikanisal (ketoconazole) is a topical antifungal employed in the treatment of common superficial fungal skin disorders, acting directly on the pathogen on the skin surface. - Tinea corporis (ringworm): reduces fungal growth, alleviates redness and scaling, leading to lesion clearance. - Tinea cruris (jock itch): diminishes itching and erythema while eradicating the causative dermatophyte. - Seborrheic dermatitis: decreases Malassezia colonisation, relieving flaking and erythema on scalp and face. - Pityriasis versicolor: suppresses Malassezia species, improving discoloration and scaling.

Topical ketoconazole may cause local skin reactions; most are mild and reversible, while rare systemic or severe cutaneous events have been reported.

Common Side Effects: - Skin irritation: mild redness or discomfort at the application site. - Burning sensation: transient heat feeling shortly after applying. - Itching: occasional pruritus that usually resolves with continued use. - Dryness: flaking or roughness of the treated skin.

Serious or Rare Side Effects: - Allergic contact dermatitis: swelling, intense itching, and rash requiring medical attention. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe blistering and skin detachment, a medical emergency. - Photosensitivity: increased sensitivity to sunlight leading to sunburn‑like reactions. - Systemic hepatic enzyme elevation: rare increase in liver enzymes after extensive use or large‑area application.

When using Mikanisal, several precautions help minimize irritation and ensure safe therapy. - Avoid use on broken skin: applying to cuts, abrasions, or eczema may increase systemic absorption and cause irritation. - Do not apply to eyes, mucous membranes, or genital area: the formulation is not intended for these sites and may cause severe discomfort. - Limit application to the affected area: avoid covering large surface areas to reduce the risk of systemic exposure. - Discontinue use and seek medical advice if severe irritation, swelling, or allergic reaction develops. - Store at room temperature: keep in the original container, protect from moisture and light.

Ketoconazole can interact with other topical agents and systemic medications, primarily through enzyme inhibition or additive skin effects.

Major Interactions (Avoid): - Concurrent use with other topical azole antifungals: may increase local irritation. - Application together with potent topical corticosteroids on the same site: may reduce antifungal efficacy. - Use with systemic ketoconazole: additive systemic exposure may increase risk of hepatic toxicity.

Moderate Interactions (Monitor Closely): - Co‑application with products containing alcohol or fragrance: may heighten skin irritation. - Use with phototoxic agents (e.g., retinoids): may enhance photosensitivity. - Combination with oral anticoagulants (e.g., warfarin) when large areas are treated: monitor coagulation parameters.